American Journal of Respiratory and Critical Care Medicine | 2021
Sleep Apnea and Poor COVID-19 Outcomes: Beware of Causal Intermediates and Colliders
Abstract
1. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012;307:157–164. 2. Semler MW, Self WH, Rice TW. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018;378:1951. 3. Pfortmueller CA, Fleischmann E. Acetate-buffered crystalloid fluids: current knowledge, a systematic review. J Crit Care 2016;35:96–104. 4. O’Malley CMN, Frumento RJ, Bennett-Guerrero E. Intravenous fluid therapy in renal transplant recipients: results of a US survey. Transplant Proc 2002;34:3142–3145. 5. Toporek AH, Casey JD, Siew ED, Rice TW, Semler MW. Effects of balanced crystalloid versus saline in patients with hyperkalemia, a retrospective analysis of the SMART trial [abstract]. Am J Respir Crit Care Med 2019;199:A5991. 6. Young P, Bailey M, Beasley R, Henderson S, Mackle D, McArthur C, et al.; SPLIT Investigators; ANZICS CTG. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA 2015;314:1701–1710. [Published erratum appears in JAMA 314:2570.] 7. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179–c184. 8. American Heart Association. Part 8: advanced challenges in resuscitation. Section 1: life-threatening electrolyte abnormalities. European Resuscitation Council. Resuscitation 2000;46:2530–259. 9. Potura E, Lindner G, Biesenbach P, Funk G-C, Reiterer C, Kabon B, et al. An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: a prospective randomized controlled trial. Anesth Analg 2015;120:123–129. 10. Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ 2016;40:480–490.